Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Autor: Colhoun, Helen M., Lingvay, Ildiko, Brown, Paul M., Deanfield, John, Brown-Frandsen, Kirstine, Kahn, Steven E., Plutzky, Jorge, Node, Koichi, Parkhomenko, Alexander, Rydén, Lars, Wilding, John P. H., Mann, Johannes F. E., Tuttle, Katherine R., Idorn, Thomas, Rathor, Naveen, Lincoff, A. Michael
Zdroj: Nature Medicine; 20240101, Issue: Preprints p1-9, 9p
Abstrakt: The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n= 8,803) versus placebo (n= 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min−11.73 m−2, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P= 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min−11.73 m−2(95% CI 0.43, 1.06; P< 0.001) overall and 2.19 ml min−11.73 m−2(95% CI 1.00, 3.38; P< 0.001) in patients with baseline eGFR <60 ml min−11.73 m−2. These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes.
Databáze: Supplemental Index
Externí odkaz: